Moderna announced on Tuesday that it expects to generate between $8 billion and $15 billion in sales from its respiratory vaccines, including Covid, RSV, flu, and other respiratory illnesses, by 2027. The biotech firm also stated that it expects to see an operating profit of $4 billion to $9 billion during the same period. Moderna…